TY - JOUR
T1 - Atrial fibrillation progression after cryoablation vs. radiofrequency ablation
T2 - the CIRCA-DOSE trial
AU - Andrade, Jason G.
AU - Deyell, Marc W.
AU - Khairy, Paul
AU - Champagne, Jean
AU - Leong-Sit, Peter
AU - Novak, Paul
AU - Sterns, Lawrence
AU - Roux, Jean Francois
AU - Sapp, John
AU - Bennett, Richard
AU - Bennett, Matthew
AU - Hawkins, Nathaniel
AU - Sanders, Prashanthan
AU - MacLe, Laurent
N1 - Funding Information:
Dr. Andrade reports grants and personal fees from Medtronic and personal fees from Biosense Webster, Boston Scientific, and St. Jude Medical/Abbott; Dr. Deyell reports grants from Biosense Webster; Dr. Leong-Sit reports personal fees from Boston Scientific and personal fees from Biosense Webster; Dr. Sapp reports grants from Biosense Webster, grants and personal fees from St. Jude Medical/Abbott, and personal fees from Medtronic; Dr. Macle reports personal fees from Medtronic and grants and personal fees from St. Jude Medical/Abbott and Biosense Webster; Dr Sanders reports grants and personal fees from Medtronic, grants and personal fees from Biosense Webster, grants and personal fees from Abbott Medical, grants from Becton Dickenson, personal fees from CathRx, and personal fees from Pacemate; Dr. Roux reports personal fees from Biosense Webster and Medtronic; Dr. M. Bennett has nothing to disclose; Dr. R. Bennett has nothing to disclose; Dr. Hawkins has nothing to disclose; Dr. Novak has nothing to disclose; Dr. Champagne has nothing to disclose; Dr. Sterns has nothing to disclose; Dr. Khairy has nothing to disclose.
Funding Information:
The trial was funded by a peer-reviewed grant from the Heart and Stroke Foundation of Canada (grant number G-13-0003121), with additional unrestricted financial support from Medtronic and Heart Rhythm Services at the University of British Columbia. The funding sources were not involved in study design; selection or monitoring of the participating centers; selection or enrollment of patients; data collection, storage, or analysis; data interpretation; manuscript preparation; or the decision to submit the manuscript for publication.
Funding Information:
The CIRCA-DOSE study was funded by a peer-reviewed grant from the Heart and Stroke Foundation of Canada (grant number G-13-0003121), with additional financial support from Medtronic. Drs. Andrade and Deyell are supported by a Michael Smith Foundation for Health Research Scholar Award. Dr. Khairy is supported by the André Chagnon research chair in electrophysiology and congenital heart disease. The funding sources had no role in the design of this study and did not have any role during its execution, analyses, interpretation of the data, or decision to submit results.
Publisher Copyright:
© 2023 The Author(s).
PY - 2024/2/14
Y1 - 2024/2/14
N2 - Background and Aims: Atrial fibrillation (AF) is a chronic progressive disorder. Persistent forms of AF are associated with increased rates of thromboembolism, heart failure, and death. Catheter ablation modifies the pathogenic mechanism of AF progression. No randomized studies have evaluated the impact of the ablation energy on progression to persistent atrial tachyarrhythmia. Methods: Three hundred forty-six patients with drug-refractory paroxysmal AF were enrolled and randomly assigned to contact-force-guided RF ablation (CF-RF ablation, 115), 4 min cryoballoon ablation (CRYO-4, 115), or 2 min cryoballoon ablation (CRYO-2, 116). Implantable cardiac monitors placed at study entry were used for follow-up. The main outcome was the first episode of persistent atrial tachyarrhythmia. Secondary outcomes included atrial tachyarrhythmia recurrence and arrhythmia burden on the implantable monitor. Results: At a median of 944.0 (interquartile range [IQR], 612.5-1104) days, 0 of 115 patients (0.0%) randomly assigned to CF-RF, 8 of 115 patients (7.0%) assigned to CRYO-4, and 5 of 116 patients (4.3%) assigned to CRYO-2 experienced an episode of persistent atrial tachyarrhythmia (P =. 03). A documented recurrence of any atrial tachyarrhythmia ≥30 s occurred in 56.5%, 53.9%, and 62.9% of those randomized to CF-RF, CRYO-4, and CRYO-2, respectively; P =. 65. Compared with that of the pre-ablation monitoring period, AF burden was reduced by a median of 99.5% (IQR 94.0%, 100.0%) with CF-RF, 99.9% (IQR 93.3%-100.0%) with CRYO-4, and 99.1%% (IQR 87.0%-100.0%) with CRYO-2 (P =. 38). Conclusions: Catheter ablation of paroxysmal AF using radiofrequency energy was associated with fewer patients developing persistent AF on follow-up.
AB - Background and Aims: Atrial fibrillation (AF) is a chronic progressive disorder. Persistent forms of AF are associated with increased rates of thromboembolism, heart failure, and death. Catheter ablation modifies the pathogenic mechanism of AF progression. No randomized studies have evaluated the impact of the ablation energy on progression to persistent atrial tachyarrhythmia. Methods: Three hundred forty-six patients with drug-refractory paroxysmal AF were enrolled and randomly assigned to contact-force-guided RF ablation (CF-RF ablation, 115), 4 min cryoballoon ablation (CRYO-4, 115), or 2 min cryoballoon ablation (CRYO-2, 116). Implantable cardiac monitors placed at study entry were used for follow-up. The main outcome was the first episode of persistent atrial tachyarrhythmia. Secondary outcomes included atrial tachyarrhythmia recurrence and arrhythmia burden on the implantable monitor. Results: At a median of 944.0 (interquartile range [IQR], 612.5-1104) days, 0 of 115 patients (0.0%) randomly assigned to CF-RF, 8 of 115 patients (7.0%) assigned to CRYO-4, and 5 of 116 patients (4.3%) assigned to CRYO-2 experienced an episode of persistent atrial tachyarrhythmia (P =. 03). A documented recurrence of any atrial tachyarrhythmia ≥30 s occurred in 56.5%, 53.9%, and 62.9% of those randomized to CF-RF, CRYO-4, and CRYO-2, respectively; P =. 65. Compared with that of the pre-ablation monitoring period, AF burden was reduced by a median of 99.5% (IQR 94.0%, 100.0%) with CF-RF, 99.9% (IQR 93.3%-100.0%) with CRYO-4, and 99.1%% (IQR 87.0%-100.0%) with CRYO-2 (P =. 38). Conclusions: Catheter ablation of paroxysmal AF using radiofrequency energy was associated with fewer patients developing persistent AF on follow-up.
KW - Ablation
KW - Atrial fibrillation
KW - Cryoablation
KW - Implantable loop recorder
KW - Insertable cardiac monitor
KW - Pulmonary vein isolation
KW - Radiofrequency Ablation
UR - https://www.scopus.com/pages/publications/85185259376
U2 - 10.1093/eurheartj/ehad572
DO - 10.1093/eurheartj/ehad572
M3 - Article
C2 - 37624879
AN - SCOPUS:85185259376
SN - 0195-668X
VL - 45
SP - 510
EP - 518
JO - European heart journal
JF - European heart journal
IS - 7
ER -